CONSTRUCTS AND LIBRARIES COMPRISING ANTIBODY SURROGATE LIGHT CHAIN SEQUENCES
The invention concerns constructs and libraries comprising antibody surrogate light chain sequences. In particular, the invention concerns constructs comprising VpreB sequences, optionally partnered with another polypeptide, such as, for example, antibody heavy chain variable domain sequences, and libraries containing the same.
1 - 88 . (canceled)
89 . A trimeric polypeptide complex comprising
(a) a VpreB sequence; a λ5 sequence or an antibody light chain constant region sequence; and an antibody heavy chain sequence, or
(b) a λ5 sequence; an antibody light chain variable region sequence; and an antibody heavy chain sequence,
wherein said sequences are non-covalently associated with each other; and
wherein said trimeric polypeptide complex binds to a target.
90 . The complex of claim 89 , comprising a VpreB1 sequence.
91 . The complex of claim 90 , comprising all or part of a VpreB1 sequence of SEQ ID NO: 1.
92 . The complex of claim 89 , comprising all or part of a λ5 sequence of SEQ ID NO: 6.
93 . The complex of claim 91 , comprising all or part of a λ5 sequence of SEQ ID NO: 6.
94 . The complex of claim 91 , wherein at least part of the C-terminal tail of said VpreB1 sequence is removed.
95 . The complex of claim 93 , wherein at least part of the N-terminal tail of said λ5 sequence is removed.
96 . The complex of claim 93 , wherein at least part of the C-terminal tail of said VpreB1 sequence and at least part of the N-terminal tail of said λ5 sequence is removed.
97 . The complex of claim 94 , wherein the entire C-terminal tail of said VpreB1 sequence is removed.
98 . The complex of claim 95 , wherein the entire N-terminal tail of said λ5 sequence is removed.
99 . The complex of claim 98 , comprising at least part of the C-terminal tail of said VpreB1 sequence.
100 . The complex of claim 99 , comprising the entire C-terminal tail of said VpreB1 sequence.
101 . The complex of claim 96 , wherein the entire C-terminal tail of said VpreB1 sequence and the entire N-terminal tail of said λ5 sequence is removed.
102 . The complex of claim 89 comprising a full-length VpreB1 sequence of SEQ ID NO: 1, and a λ5 sequence of SEQ ID NO: 6 having at least part of its N-terminal tail removed.
103 . The complex of claim 102 comprising a full-length VpreB1 sequence of SEQ ID NO: 1, and a λ5 sequence of SEQ ID NO: 6 having its N-terminal tail removed.
104 . The complex of claim 89 comprising a full-length λ5 sequence of SEQ ID NO: 6, and a VpreB1 sequence of SEQ ID NO: 1 having at least part of its C-terminal tail removed.
105 . The complex of claim 104 comprising a full-length λ5 sequence of SEQ ID NO: 6, and a VpreB1 sequence of SEQ ID NO: 1 having its C-terminal tail removed.
106 . The complex of claim 89 comprising a full-length VpreB1 sequence of SEQ ID NO: 1 and a full-length λ5 sequence of SEQ ID NO: 6.
107 . The complex of claim 89 , comprising at least one additional functionality appended or substituted to a free end of the λ5 sequence and/or a free end of the VpreB sequence.
108 . The complex of claim 98 , comprising at least one additional functionality appended or substituted to a free end of the λ5 sequence and/or a free end of the VpreB1 sequence.
109 . The complex of claim 89 , wherein the complex comprises (a) a VpreB sequence, an antibody light chain constant region, and an antibody heavy chain sequence.
110 . A library comprising a complex of any one of claims 89 .
111 . A library comprising the complex of claim 107 .
112 . The library of claim 111 comprising a random peptide library appended or substituted to said N-terminal or C-terminal tail present and panned for specific binding to a further target.
113 . The library of claim 111 comprising an antibody or antibody fragment appended or substituted to said N-terminal or C-terminal tail present.
114 . The library of claim 113 wherein said antibody or antibody fragment binds to the same target as said complex.
115 . The library of claim 113 wherein said antibody or antibody fragment binds to a target different from the target to which said complex binds.
116 . The library of claim 114 wherein said antibody or antibody fragment binds to a tumor antigen.
117 . The library of claim 115 wherein said antibody or antibody fragment binds to a tumor antigen.
118 . The library of claim 111 comprising a therapeutic peptide or therapeutic protein appended or substituted to said N-terminal or C-terminal tail present.